Literature DB >> 21466488

Natural history of ulcerative colitis: current knowledge.

Lajos Sandor Kiss1, Peter Laszlo Lakatos.   

Abstract

The clinical presentation at the time of diagnosis and the disease course of ulcerative colitis (UC) are heterogeneous and variable over time. In population-based epidemiological follow-up studies from the last decades, the extent of UC has shown only slight variation. At diagnosis, the initial extent is evenly distributed among proctitis, left-sided, and extensive colitis with some exceptions. The disease course may vary from a single attack to chronic symptoms that reduce the quality of life as well as lead to disease extension, colectomy or even to the development of colitis-associated colorectal cancer in some cases. Important predictive clinical factors and biomarkers of disease course have been under increasing scrutiny. Those identified may eventually lead to a more personalized, tailored therapy. In this review article, the authors summarize the available evidence on the natural history and predictive markers for evaluating the course of UC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466488     DOI: 10.2174/138945011796818117

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  6 in total

1.  Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation between Prognosis and Disease Susceptibility Loci.

Authors:  Kasumi Hishinuma; Rintaro Moroi; Daisuke Okamoto; Yusuke Shimoyama; Masatake Kuroha; Hisashi Shiga; Yoichi Kakuta; Yoshitaka Kinouchi; Atsushi Masamune
Journal:  Inflamm Intest Dis       Date:  2021-09-02

Review 2.  Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis.

Authors:  Bruno César da Silva; Andre Castro Lyra; Raquel Rocha; Genoile Oliveira Santana
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

3.  Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.

Authors:  Michael D Mandel; Mandel D Michael; Anita Bálint; Barbara D Lovász; László Gulácsi; Bálint Strbák; Petra A Golovics; Klaudia Farkas; Zsuzsanna Kürti; Blanka K Szilágyi; Anna Mohás; Tamás Molnár; Péter L Lakatos
Journal:  Eur J Health Econ       Date:  2014-05-16

Review 4.  Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.

Authors:  Robin J Dart; Mark A Samaan; Nick Powell; Peter M Irving
Journal:  Clin Exp Gastroenterol       Date:  2017-03-03

5.  Sigmoidoscopic extent of ulcerative colitis and associated factors in Pakistani population.

Authors:  Asim Saleem; Mubashar Zeeshan; Faryal Hazoor; Ghulam Mustafa
Journal:  Pak J Med Sci       Date:  2022 Jan-Feb       Impact factor: 1.088

6.  The Demographic and Clinical Characteristics of Ulcerative Colitis in a Northeast Brazilian Population.

Authors:  Bruno César da Silva; Andre Castro Lyra; Carlos Maurício Cardeal Mendes; Camila Paula Oliveira Ribeiro; Sonyara Rauedys Oliveira Lisboa; Mariana Tinoco Lordello de Souza; Renata Cavalcanti Portela; Genoile Oliveira Santana
Journal:  Biomed Res Int       Date:  2015-10-05       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.